Kesios Therapeutics Limited is a UK-based biotechnology company developing novel therapeutics for the treatment of multiple myeloma and other cancers where there are significant unmet medical needs.
The company is focused on the discovery and development of novel drug candidates for the treatment of multiple myeloma and other malignancies which target aberrant NF-κB signaling, via a novel drug target (the GADD45β/MKK7 complex). The NF-κB signaling pathway is involved in driving normal cell death but when aberrantly activated allows cancer cells to survive.
The company has established a pipeline of programmes targeting this pathway, with KES-0001, the company’s lead drug candidate, about to enter clinical studies as a potential treatment for multiple myeloma. Additional pre-clinical research programmes will explore KES-0001 in haematological malignancies, colon cancer and other solid tumors.
Kesios is led by an experienced management team and is supported by a syndicate of leading international investors. The company operates from offices and laboratories based at the Imperial College Incubator, London, UK.
Company Details
- Founded
- -
- Phone
- 4402038189280
- in****@****ios.com
- Industry
- Biotechnology
- Website
- kesios.com
- Keywords
- IT Consulting.
Kesios Therapeutics Questions
Kesios Therapeutics's helpline number is 4402038189280
Kesios Therapeutics's website is kesios.com
Kesios Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/kesios-therapeutics
Kesios Therapeutics's industry is
Biotechnology
Kesios Therapeutics's top competitors are
Valirx Plc,
Oxsonics Therapeutics,
Napp Pharmaceuticals Limited,
Cellcentric,
Bloomsbury Genetic Therapies,
Accession Therapeutics Limited,
Nucana Plc,
Locomizer,
Gammadelta Therapeutics,
Liverpool Clinical Laboratories (Lcl).
Kesios Therapeutics's support email address is info@kesios.com
Kesios Therapeutics's categories are Biotechnology
Kesios Therapeutics's founding year is 2012
